Research Analysts Offer Predictions for Teleflex Q2 Earnings

Teleflex Incorporated (NYSE:TFX - Free Report) - Stock analysts at Zacks Research decreased their Q2 2025 earnings estimates for Teleflex in a research report issued to clients and investors on Tuesday, June 24th. Zacks Research analyst R. Department now anticipates that the medical technology company will earn $3.34 per share for the quarter, down from their prior estimate of $3.35. The consensus estimate for Teleflex's current full-year earnings is $13.98 per share. Zacks Research also issued estimates for Teleflex's Q3 2025 earnings at $3.36 EPS, Q4 2025 earnings at $3.72 EPS, FY2025 earnings at $13.33 EPS, Q3 2026 earnings at $3.78 EPS, Q4 2026 earnings at $3.51 EPS and FY2026 earnings at $13.74 EPS.

Teleflex (NYSE:TFX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.88 by $0.03. Teleflex had a net margin of 4.96% and a return on equity of 14.73%. The firm had revenue of $700.67 million during the quarter, compared to analyst estimates of $699.37 million. During the same quarter in the prior year, the business posted $3.21 earnings per share. The company's quarterly revenue was down 5.0% compared to the same quarter last year.

TFX has been the subject of several other research reports. Mizuho set a $155.00 price target on shares of Teleflex in a research report on Wednesday, April 16th. Royal Bank Of Canada dropped their price objective on shares of Teleflex from $150.00 to $145.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. Morgan Stanley dropped their price objective on shares of Teleflex from $191.00 to $173.00 and set an "overweight" rating for the company in a report on Monday, May 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of Teleflex in a report on Wednesday, March 12th. Finally, Wall Street Zen lowered shares of Teleflex from a "buy" rating to a "hold" rating in a report on Sunday. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $164.63.

Teleflex Price Performance

NYSE:TFX traded down $0.16 during mid-day trading on Thursday, hitting $119.42. The company's stock had a trading volume of 712,257 shares, compared to its average volume of 627,870. Teleflex has a fifty-two week low of $115.94 and a fifty-two week high of $249.91. The company has a current ratio of 2.28, a quick ratio of 1.32 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $5.28 billion, a price-to-earnings ratio of 37.67, a P/E/G ratio of 1.87 and a beta of 1.10. The stock has a fifty day moving average of $124.41 and a 200-day moving average of $147.33.

Teleflex Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 16th. Shareholders of record on Tuesday, May 20th were issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 1.14%. The ex-dividend date was Tuesday, May 20th. Teleflex's dividend payout ratio is presently 42.90%.

Institutional Trading of Teleflex

A number of institutional investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. grew its holdings in shares of Teleflex by 0.7% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 6,216,763 shares of the medical technology company's stock valued at $859,095,000 after buying an additional 43,642 shares during the period. Geode Capital Management LLC grew its holdings in shares of Teleflex by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 1,138,867 shares of the medical technology company's stock valued at $202,161,000 after buying an additional 8,307 shares during the period. Cooke & Bieler LP grew its holdings in shares of Teleflex by 22.1% in the 4th quarter. Cooke & Bieler LP now owns 1,078,557 shares of the medical technology company's stock valued at $191,962,000 after buying an additional 195,150 shares during the period. Invesco Ltd. grew its holdings in shares of Teleflex by 48.1% in the 4th quarter. Invesco Ltd. now owns 1,068,593 shares of the medical technology company's stock valued at $190,188,000 after buying an additional 347,003 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Teleflex by 69.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 867,864 shares of the medical technology company's stock valued at $119,927,000 after buying an additional 355,720 shares during the period. Institutional investors and hedge funds own 95.62% of the company's stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.